CLINICAL EXPERIENCE OF USING SUBMILISECOND Nd:YAG-LASER RADIATION 1064 NM AND CREAM WITH 1% OF IVERMEKTIN FOR TREATMENT OF PAPULOPUSTULAR FORM OF ROSACEA

Abstract

Rosacea is a polyethiological disease at the base of it progress is pathologically changed innervation of vessels of the skin of face - angioneurosis and it undergoes several stages of development. Initially, against the background of permanent extension, the vascular wall loses elasticity and the blood plasma penetrates it. Microcirculation disorders lead to hypostasis of tissues. This process leads to change of a biota of the face skin - to the uncontrollable growth of number of a Demodex tick, which is one of the ethyopathogenetics factor of promotion from erythemoteleangiectatic form to papulopustular. Etiological reasonable approach for therapy of papulopustular rosacea is a combination of external and physiotherapeutic methods of therapy. As medicamentous therapy for suppression of excess activity of a Demodex tick and its uncontrollable growth in our research we have taken the cream with 1% of Ivermektin. As a physiotherapeutic influence - the submilisecond Nd:YAG-laser radiation (1064 nm). This radiation influences at expanded vessels, sanifies pustules, moderate temperature increase in a derma to 41-42оС, leads to elimination of puffiness and stage-by-stage restructuring of collagen fibers.

Keywords

laser therapy / Rosacea / submilisecond Nd:YAG 1064 nm laser / vascular damages of skin / angioneurosis

References

[1] Кубанова А.А. (ред.) Клинические рекомендации. Дерматовенерология. М.; 2010: 203.

[2] Круглова Л.С., Котенко К.В., Корчажкина Н.Б., Турбовская С.Н. Физиотерапия в дерматологии. М.; 2016.

[3] McAleer M.A., Fitzpatrick P., Powell F.C. Papulopustular rosacea: prevalence and relationship to photodamage. J. Am. Acad. Dermatol. 2010; 63: 33-9.

[4] Steinhoff M., Buddenkotte J., Aubert J., Sulk M., Novak P., Schwab V.D. et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J. Invest. Dermatol. Symp. Proc. 2011; 15(1): 2-11.

[5] Gerber P.A., Buhren B.A., Steinhoff M., Homey B. Rosacea: the cytokine and chemokine network. J. Invest. Dermatol. Symp. Proc.; 2011; 15(1): 40-7.

[6] Woo Y.R., Lim J.H., Cho D.H., Park H.J. Rosacea: molecular mechanisms and management of a chronic cutaneous inflammatory condition. Int. J. Mol. Sci. 2016; 17(9): Е1562.

[7] Yamasaki K., Kanada K., Macleod D.T., Borkowski A.W., Morizane C., Nakatsuji T. et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J. Invest. Dermatol. 2011; 131(3): 688-97.

[8] Zhang J., Xu X., Rao N.V., Argyle B., McCoard L., Rusho W.J. et al. Novel sulfated polysaccharides disrupt cathelicidins, inhibit rage and reduce cutaneous inflammation in a mouse model of rosacea. PLoS One. 2011; 6(2): e16658.

[9] Самцов А.В. Акне и акнеформные дерматозы. М.; 2014: 193.

[10] Sattler E.C., Maier T., Hoffman V.S., Hegyi J., Ruzicka T., Berking C. Noninvasive in vivo detection and quantification of Demodex mites by confocal laser scanning microscopy. Br. J. Dermatol. 2012; 167: 1042-7.

[11] Forton F. Papulopustular rosacea, skin immunity and Demodex: pityriasis folloculorum as a missing link. J. Eur. Acad. Dermatol. Venereol. 2012; 26(1): 19-28.

[12] Gerber P.A., Buhren B.A., Steinhoff M., Homey B. Rosacea: the сytokine and сhemokine network. J. Invest. Dermatol. 2011; 15(1): 40-7.

[13] Abokwidir M., Feldman S.R. Rosacea Management. Skin Appendage Disord. 2016; 2(1-2): 26-34.

[14] Siddiqui K., Gold L.S., Gill J. The efficacy, safety, and tolerability of ivermectin compared with current topical treatments for the inflammatory lesions of rosacea: a network meta-analysis. SpringerPlus. 2016; (5): 1151.

[15] Виссарионов В.А. (ред.) Эстетические недостатки кожи. Коррекция методом дермабразии. М.; 2009: 100-8

RIGHTS & PERMISSIONS

Eco-Vector